> News > Martin Dewhurst joins the Distalmotion Board of Directors
25.05
2023

Martin Dewhurst joins the Distalmotion Board of Directors

Lausanne, 25 May 2023: Distalmotion announced the appointment of Martin Dewhurst to the Board of Directors. Martin brings over 30 years of life sciences experience from his time at McKinsey where he led the global life sciences practice for 7 years (2014 to 2021). He has served clients globally acrosspharma, medical devices and consumer health –from early-stage ventures to the most respected global leaders. Most recently, he co-founded and co-ledthe McKinsey Health Institute, a non-profit generating entity focused on some of the world most importanthealth challenges. Until 2014, Martin led McKinsey’s pan-industry organization practice in EMEA.

“I am pleased to welcome Martin Dewhurst to our team,” expressed Rick Anderson, Chairman of the Board for Distalmotion. “Martin has unique insights, expertiseand world class relationships with global healthcare decision makers and will play a crucial role in advancing Distalmotion. Martin’s presence on the board further demonstrates our commitment to building a strong and experienced leadership team and board of directors.”

Martin Dewhurst expressed his enthusiasm for joining Distalmotion team, stating, "I am grateful to have the opportunity to join the Board of such an exciting company at such an exciting time in their growth. Distalmotion is establishing a new paradigm in the soft tissue robotic surgery space –one where surgeons have the flexibility to deploy robotics where it makes the biggest difference during a procedure. The Dexter system is already demonstrating its relevance and versatility across adopter sites in Europe. I am delighted to work with the Board and the leadership team on what will be a great journey."

By appointing this new member to our Board of Directors, we are taking a significant step towards advancing our company's strategy. As we continue to work towards our submission to the US Food and Drug Administration (FDA), we are confident that our strengthened leadership team will be well-equipped todrive our business forward."We are thrilled to welcome Martin Dewhurst to our Board," said Distalmotion's CEO Michael Friedrich. "His extensive experience and strategic thinking will provide valuable perspectives as we tackle new challenges and pursue growth opportunities. We look forward to working together to drive the future success of our company."

Company related to the news